Alnylam director exercises options for 11,250 shares

ALNYLAM PHARMACEUTICALS director Amy W. Schulman exercised stock options to acquire 11,250 shares of common stock at $70.20 per share.

Rhea-AI Filing Summary

ALNYLAM PHARMACEUTICALS director Amy W. Schulman exercised stock options to acquire 11,250 shares of common stock at $70.20 per share. These options were due to expire on June 3, 2026, and the exercise occurred on May 13, 2026. Following the transaction, she directly holds 23,211 common shares. The corresponding stock option position for these 11,250 shares has been fully exercised, with no remaining options from this grant shown in the filing.

Insider Trade Summary

11,250 shares exercised/converted

Exercise 2 txns

Insider SCHULMAN AMY W

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	11,250	$0.00	$0.00
Exercise	Common Stock	11,250	$70.20	$790K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 23,211 shares (Direct)

Footnotes (1)

1. F1. The options exercised and held by the reporting person were due to expire on June 3, 2026.

Key Figures

Options Exercised: 11,250 shares Exercise Price: $70.20 per share Shares Held After: 23,211 shares +3 more

6 metrics

Options Exercised 11,250 shares Stock options converted to common stock on May 13, 2026

Exercise Price $70.20 per share Conversion or exercise price for the stock options

Shares Held After 23,211 shares Total common shares directly held after the transaction

Options Exercised (Derivative Line) 11,250 shares Underlying common stock for exercised Stock Option (Right to Buy)

Option Expiration June 3, 2026 Footnote: options exercised were due to expire on this date

Exercise Count 1 exercise, 11,250 shares Form 4 transaction summary for derivative exercises

Key Terms

Stock Option (Right to Buy), derivative security, conversion or exercise price, Form 4

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" tied to 11,250 shares"

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

conversion or exercise price financial

"conversion_or_exercise_price: "70.2000" for the stock option"

Form 4 regulatory

"INSIDER FILING DATA (Form 4) for ALNYLAM PHARMACEUTICALS, INC."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ALNY director Amy W. Schulman report?

Amy W. Schulman reported exercising stock options to acquire 11,250 shares of ALNYLAM common stock. The transaction was recorded as a derivative exercise, converting options into shares rather than an open-market purchase or sale.

At what price did Amy W. Schulman exercise her ALNY stock options?

She exercised stock options with a conversion or exercise price of $70.20 per share. This exercise converted 11,250 option rights into 11,250 shares of ALNYLAM common stock on May 13, 2026, according to the Form 4 filing.

How many ALNY shares does Amy W. Schulman hold after this Form 4 transaction?

After the reported exercise, Amy W. Schulman directly holds 23,211 shares of ALNYLAM common stock. This figure reflects her position following the conversion of 11,250 stock options into common shares in the May 13, 2026 transaction.

What happened to Amy W. Schulman’s ALNY stock options in this filing?

Schulman exercised 11,250 stock options labeled as a “Stock Option (Right to Buy).” After the exercise, the filing shows zero remaining shares under this option, indicating that this particular option grant has been fully used.

When were Amy W. Schulman’s exercised ALNY options due to expire?

The exercised options were due to expire on June 3, 2026. A footnote explains that the options exercised and held by the reporting person were approaching this expiration date, which likely prompted the May 13, 2026 exercise.

Does the ALNY Form 4 show any stock sales by Amy W. Schulman?

The Form 4 shows no open-market sales; it records only an option exercise. The transaction codes and summary classify the activity as a derivative exercise, acquiring shares rather than selling them, with net buy/sell direction reported as neutral.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 04:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHULMAN AMY W

(Last) (First) (Middle)

675 WEST KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/13/2026		M(1)		11,250	A	$70.2	23,211	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$70.2	05/13/2026		M(1)			11,250	06/03/2017	06/03/2026	Common Stock	11,250	$0	0	D

Explanation of Responses:

1. The options exercised and held by the reporting person were due to expire on June 3, 2026.

	/s/ Brett Budzinski, attorney-in-fact for Amy W. Schulman	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)